Women’s imaging encompasses many radiology procedures related to women and the diseases that are most prevalent to women such as breast cancer or gynecological issues. Mammogram, breast ultrasound, breast MRI and breast biopsy are the most commonly used procedures.
A team of experts determined that correlating masses initially detected on MRI are significantly more likely to result in a cancer diagnosis than other common findings.
This latest research further confirms that breast MRI not only detects tumors that mammography cannot, but it also spots invasive cases that pose greater risks to patients.
Experts, medical organizations and advocates alike are coming forward saying that the new guidelines “do not go far enough,” particularly when it comes to addressing the screening needs of certain patients.
Research has once again shown that false-positive screening mammography results lead to increased anxiety for the women that receive them, and that these feelings can last for months. But how much should we fear the fear itself?
Human trials are still a few years off, but a new contrast agent for early-detection breast MRI has come through biomedical imaging investigations in mice with flying colors.
The DENSE Trial, the first randomized trial investigating the additional value of MRI for screening women with dense breasts, is featured in the current issue of Radiology.
A congresswoman with a personal breast cancer story joined imaging experts for a Capitol Hill briefing that served both to illuminate the importance of mammography screening and also condemn recent U.S. Preventive Services Task Force mammography guidelines.
Volpara Solutions today announced the release of VolparaDensity version 3.1 here at the Society of Breast Imaging’s SBI/ACR Breast Imaging Symposium in Orlando, Fla., April 25-28, 2015 (SBI Booth #214).
The cancer detection rate was significantly lower for breast MRI screenings than for diagnostic MRIs, according to a study published in the September issue of the Journal of the American College of Radiology.
Matakina International today announced that ProMedica Breast Care on the campus of ProMedica Toledo Hospital became the first in Ohio to offer VolparaDensity™ breast imaging software, designed to help overcome the limitations of mammography to detect cancer in women with dense breasts. Serving Northwest Ohio and Southeast Michigan, the Toledo Hospital Breast Care Center is the region’s premier imaging facility devoted exclusively to patients with breast health concerns and issues and has been named a Breast Imaging Center of Excellence by the American College of Radiology.
Automated AI-generated measurements combined with annotated CT images can improve treatment planning and help referring physicians and patients better understand their disease, explained Sarah Jane Rinehart, MD, director of cardiac imaging with Charleston Area Medical Center.
Two advanced algorithms—one for CAC scores and another for segmenting cardiac chamber volumes—outperformed radiologists when assessing low-dose chest CT scans.
"Gen AI can help tackle repetitive tasks and provide insights into massive datasets, saving valuable time," Thomas Kurian, CEO of Google Cloud, said Tuesday.